Published in Peptides on January 22, 2009
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) (2009) 0.81
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology (Berl) (2010) 0.78
Stress-induced decreases in local cerebral glucose utilization in specific regions of the mouse brain. BMC Res Notes (2011) 0.77
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci (2003) 2.37
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem (2005) 2.03
Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci (2006) 2.01
Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol (2005) 2.00
Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J Neurosci (2002) 1.94
Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc Natl Acad Sci U S A (2002) 1.18
JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology (2004) 1.16
NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology (2011) 1.16
Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci (2002) 1.15
Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm (2013) 1.14
Blocking melanin-concentrating hormone MCH1 receptor affects rat sleep-wake architecture. Eur J Pharmacol (2007) 1.13
In vivo electroporation of the central nervous system: a non-viral approach for targeted gene delivery. Prog Neurobiol (2010) 1.05
Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem (2003) 1.05
Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol (2004) 1.04
Mammalian Navigators are microtubule plus-end tracking proteins that can reorganize the cytoskeleton to induce neurite-like extensions. Cell Motil Cytoskeleton (2009) 1.03
Role of ghrelin in the relationship between hyperphagia and accelerated gastric emptying in diabetic mice. Gastroenterology (2008) 1.03
[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol (2003) 1.01
Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure. Neuropsychopharmacology (2011) 0.98
Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res (2005) 0.98
Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem (2003) 0.97
Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. J Med Chem (2013) 0.97
IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology (2007) 0.96
Impairment of VGLUT2 but not VGLUT1 signaling reduces neuropathy-induced hypersensitivity. Eur J Pain (2009) 0.96
Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Top Behav Neurosci (2010) 0.95
Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med (2010) 0.95
Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett (2012) 0.94
Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol Endocrinol (2008) 0.94
Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time. Eur J Neurosci (2004) 0.93
Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. Eur J Pharmacol (2010) 0.93
Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅). J Med Chem (2014) 0.92
The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders. Psychopharmacology (Berl) (2013) 0.91
Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127. Neuropharmacology (2004) 0.91
Chronic corticosterone manipulations in mice affect brain cell proliferation rates, but only partly affect BDNF protein levels. Neurosci Lett (2005) 0.91
Cholinergic blockade impairs performance in operant DNMTP in two inbred strains of mice. Pharmacol Biochem Behav (2002) 0.90
A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. Int J Neuropsychopharmacol (2010) 0.90
Synaptic dysfunction in hippocampus of transgenic mouse models of Alzheimer's disease: a multi-electrode array study. Neurobiol Dis (2011) 0.89
Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol (2005) 0.89
Nav2 is necessary for cranial nerve development and blood pressure regulation. Neural Dev (2010) 0.89
Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther (2013) 0.88
Reconsideration of 5-hydroxytryptamine (5-HT)(7) receptor distribution using [(3)H]5-carboxamidotryptamine and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline: analysis in brain of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice. J Pharmacol Exp Ther (2002) 0.86
Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives. Psychopharmacology (Berl) (2013) 0.86
Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. J Med Chem (2012) 0.86
Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice. Brain Res Mol Brain Res (2004) 0.85
Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology (2006) 0.85
Transcriptional response to corticotropin-releasing factor in AtT-20 cells. Mol Pharmacol (2004) 0.85
Use of a beta microprobe system to measure arterial input function in PET via an arteriovenous shunt in rats. EJNMMI Res (2011) 0.84
N-acetylcysteine- and MK-801-induced changes in glutamate levels do not affect in vivo binding of metabotropic glutamate 5 receptor radioligand 11C-ABP688 in rat brain. J Nucl Med (2013) 0.83
Nav2 hypomorphic mutant mice are ataxic and exhibit abnormalities in cerebellar development. Dev Biol (2011) 0.83
Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors. Bioorg Med Chem Lett (2012) 0.83
Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. Int J Neuropsychopharmacol (2009) 0.83
Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions. Drug Metab Dispos (2013) 0.82
Discovery and SAR of a novel series of non-MPEP site mGlu₅ PAMs based on an aryl glycine sulfonamide scaffold. Bioorg Med Chem Lett (2012) 0.82
Synaptic transmission changes in fear memory circuits underlie key features of an animal model of schizophrenia. Behav Brain Res (2011) 0.82
Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol (2008) 0.82
Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer's Disease. Curr Alzheimer Res (2015) 0.81
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) (2009) 0.81
Low Current-driven Micro-electroporation Allows Efficient In Vivo Delivery of Nonviral DNA into the Adult Mouse Brain. Mol Ther (2010) 0.81
Touching on translation. Cell Tissue Res (2013) 0.80
Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker. J Pharmacol Exp Ther (2011) 0.80
Molecular properties affecting fast dissociation from the D2 receptor. Bioorg Med Chem (2011) 0.80
Decreased expression of multidrug efflux transporters in the brains of GSK-3beta transgenic mice. Brain Res (2009) 0.80
Inactivation of the constitutively active ghrelin receptor attenuates limbic seizure activity in rodents. Neurotherapeutics (2012) 0.79
Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J Control Release (2005) 0.79
Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs. J Pharmacol Exp Ther (2014) 0.79
The high-level similarity of some disparate gene expression measures. Bioinformatics (2007) 0.79
Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging. Psychopharmacology (Berl) (2010) 0.79
Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J Pharmacol Exp Ther (2008) 0.78
Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist. Psychopharmacology (Berl) (2010) 0.78
Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem (2011) 0.78
Comparison of the ex vivo receptor occupancy profile of ketamine to several NMDA receptor antagonists in mouse hippocampus. Eur J Pharmacol (2013) 0.78
Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia. J Med Chem (2014) 0.78
MK-801 alters RGS2 levels and adenylyl cyclase sensitivity in the rat striatum. Neuroreport (2005) 0.77
Stress-induced decreases in local cerebral glucose utilization in specific regions of the mouse brain. BMC Res Notes (2011) 0.77
A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependent. J Biopharm Stat (2005) 0.77
Pharmacologic treatment of panic disorder. Curr Top Behav Neurosci (2010) 0.77
Effect of stress and peripheral immune activation on astrocyte activation in transgenic bioluminescent Gfap-luc mice. Glia (2015) 0.77
Identification of a novel orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor with efficacy in animal models of schizophrenia. J Med Chem (2015) 0.77
Behavioral neurobiology of anxiety and its treatment. Preface. Curr Top Behav Neurosci (2010) 0.76
R278995/CRA0450, a corticotropin-releasing factor (CRF(1)) receptor antagonist modulates REM sleep measures in rats: Implication for therapeutic indication. Eur J Pharmacol (2012) 0.76
Rational design and synthesis of aminopiperazinones as β-secretase (BACE) inhibitors. Bioorg Med Chem Lett (2011) 0.76
Early life stress and psychopharmacology. Psychopharmacology (Berl) (2011) 0.76
Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism. Bioorg Med Chem (2007) 0.76
Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. J Med Chem (2005) 0.76
JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease. ACS Chem Neurosci (2014) 0.76
In the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors. Acta Neurol Belg (2014) 0.76
Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping. EJNMMI Res (2013) 0.75
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives as non-peptidic selective delta-opioid agonists with potential anxiolytic/antidepressant properties. Part 2. Bioorg Med Chem Lett (2007) 0.75
Demonstration of vesicular glutamate transporter-1 in corticotroph cells in the anterior pituitary of the rat. Neurochem Int (2009) 0.75
Differential interaction of neuroleptics with apomorphine-induced behavior in rats as a function of changing levels of dopamine receptor stimulation. J Pharmacol Exp Ther (2013) 0.75
4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett (2005) 0.75